Welcome to our dedicated page for Tevogen Bio news (Ticker: TVGNW), a resource for investors and traders seeking the latest updates and insights on Tevogen Bio stock.
Tevogen Bio Holdings Inc. (Nasdaq: TVGN) is a clinical-stage biotechnology company focused on precision T cell therapies and AI-enabled drug development, and its news flow reflects this dual emphasis on science and capital-efficient execution. Company announcements highlight progress across its ExacTcell™ platform, the Tevogen Bio therapeutic pipeline, and the Tevogen.AI analytics division, as well as financial and corporate developments disclosed through SEC filings.
Readers of the Tevogen news page can expect updates on clinical and scientific milestones, such as expanded HLA coverage for its investigational T cell therapy TVGN 489, completion of target identification for additional HLA restrictions, and preclinical work in areas including EBV-associated lymphomas, chronic hepatitis B, and HPV-related cancers. The company also reports on recognition from industry and regional publications, intellectual property developments, and the evolution of its AI capabilities, including its PredicTcell™ model.
Tevogen’s news also covers financial and operational disclosures, including commentary around quarterly reports on Form 10-Q, non-GAAP metrics used by management, and statements on capital efficiency and cash burn. In addition, the company issues releases on corporate actions such as at-the-market equity programs and personal contributions by its founder and CEO to support facilities and community initiatives.
For investors and observers, following Tevogen news provides insight into how the company is advancing its precision T cell therapy programs, building out AI-driven target discovery, and managing its capital structure. Regular updates offer context on the company’s progress in infectious diseases, oncology, and neurology, as well as its stated focus on affordability and sustainable innovation.
Tevogen (Nasdaq: TVGN) reported 2025 scientific and operational milestones focused on scaling its ExacTcell™ T cell platform, expanding cytotoxic T lymphocyte (CTL) programs across viral and oncology indications, and advancing in-house GMP cell therapy manufacturing readiness. 2025 achievements include improved lab yields per product, T cell target identification for five additional HLA restrictions for SARS-CoV-2 CTLs, and target discovery work for EBV, chronic hepatitis B, and HPV-related cancers supported by Tevogen.AI.
Management highlighted platform scalability, pipeline breadth, manufacturing foundation, and plans to discuss AI, financial strategy, and commercialization at J.P. Morgan.
Tevogen (Nasdaq: TVGN) announced on December 22, 2025 that Founder and CEO Dr. Ryan Saadi donated 230,000 shares of Tevogen common stock to SRLC USA, a United Nations-recognized 501(c)(3) nonprofit serving underserved communities.
The company said the transfer was conducted in accordance with SEC Rule 144 and that Dr. Saadi will not receive any proceeds from any disposal of the securities. The donation is described as supporting education initiatives for underprivileged children.
Tevogen (Nasdaq: TVGN) Founder and CEO Dr. Ryan Saadi donated 50,000 shares of his personal Tevogen common stock to the Mt. Bethel Fire Company to support emergency readiness in Warren Township on December 19, 2025. The contributed shares are intended to enhance safety, equipment and response capabilities.
The donation was executed under SEC Rule 144, and Dr. Saadi will not receive proceeds from any disposal of the securities. The announcement also states an estimated $10 billion asset valuation for the company and a secured cash runway through commercialization.
Tevogen (Nasdaq: TVGN) announced that Founder and CEO Dr. Ryan Saadi donated 230,000 personal shares of common stock to the Warren Township Honorary Policemen’s Benevolent Association (P.B.A.) Local 235 on Dec. 11, 2025. The nonprofit supports local schools, D.A.R.E., Explorer programs, families of fallen/injured officers, and community events. The donation will fund equipment to enhance officer and resident safety. The transfer was made in accordance with SEC Rule 144 and Dr. Saadi will not receive proceeds from the disposal of the securities.
Tevogen (Nasdaq: TVGN) honored board member Curtis Patton, PhD, with a joint portrait at Yale School of Medicine recognizing his decades-long contributions to medical education, mentorship, and public health.
The portrait by Mario Moore will be unveiled on December 11, 2025 at 4 p.m. at the Harvey Cushing/John Hay Whitney Medical Library. Tevogen highlighted Dr. Patton's influence on the company as it advances the ExacTcell™ T cell platform, scales Tevogen.AI predictive technologies, and pursues growth with revenue forecasts exceeding $1 billion.
Tevogen (Nasdaq: TVGN) was named to the 2025 New Jersey Power List by NJBIZ for influence on New Jersey's economic and innovation landscape.
NJBIZ highlighted Tevogen's ExacTcell platform, advancing pipelines in infectious disease, oncology, and neurology, and its internally developed PredicTcell AI for target prediction. The recognition referenced an anticipated ~$1 billion in first-year specialty-care revenue and a cumulative five-year forecast of $18–22 billion. Tevogen also noted expansion including a 17,428-square-foot manufacturing facility and a new headquarters that more than doubles its prior footprint, centralizing R&D, regulatory, and Tevogen.AI operations.
Tevogen (Nasdaq: TVGN) filed its Form 10-Q for the quarter ended September 30, 2025, reporting continued capital-efficient execution.
Key metrics: GAAP loss from operations of $5.7M for Q3 2025 and $21.5M for the nine months ended Sept 30, 2025; Adjusted loss from operations was $2.5M (Q3) and $7.8M (nine months), representing a 10% and 25% reduction versus the comparable 2024 periods. The company highlights investments in workforce, IT, and Tevogen.AI while emphasizing cost-efficient drug development.
Tevogen (Nasdaq: TVGN) announced on Nov 5, 2025 completion of T cell target identification for five additional HLA restrictions, expanding ExacTcell™ coverage beyond the initial HLA-A*02:01.
The company says the step could extend TVGN 489 access from ~25% to approximately 65% of the U.S. population. The TVGN 489 proof-of-concept trial reported 100% viral clearance, no reinfections, and no Long COVID cases in high-risk patients.
Tevogen (Nasdaq: TVGN) clarified its reported accumulated deficit and provided cash-versus-noncash context for investors on Nov 3, 2025. The company said it has raised under $42 million in total cash to June 30, 2025, while GAAP shows an accumulated deficit of $129 million. Management explained that backing out cash yields a cash loss of ~ $41 million and about $88 million of non-cash expenses, offset by $110 million in Additional Paid-in Capital and a capital raise of over $8.8 million, leaving a stockholders’ deficit of under $9.5 million.
The company plans to publish reconciled non-GAAP metrics with its Form 10-Q for Q3 2025 and reiterated forward-looking risks including the need for additional capital.
Tevogen (Nasdaq: TVGN) outlined recent progress in making allogeneic T cell therapies more accessible, citing dose-finding clinical data for TVGN 489 and demand from Long COVID patients. Management highlighted an rNPV valuation of $9–$11 billion for TVGN 489 and a projected 5-year top-line revenue of ~ $6.5 billion for a liver-cancer prevention product targeting high-risk chronic Hepatitis B. Tevogen.AI completed alpha and began beta of PredicTcell, reported large time reductions in target analysis with potential billions in development savings, and received an international patent publication (WO2025/129197). The company expanded headquarters and created a Long COVID contact channel receiving global inquiries.
FAQ
What is the current stock price of Tevogen Bio (TVGNW)?
